Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

872
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
872
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

20
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
20
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

626
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
626
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

22
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Envelope-Limited Chromatin Sheets (ELCS) Formation in The Nuclear Envelope of HL-60/S4 Cells.

bioRxiv : the preprint server for biology·2026
Same author

Mitochondria as a Therapeutic Target for Burn Injury.

Biomolecules·2026
Same author

Nuclear Pore Complexes in Various States of HL-60/S4 Cells.

bioRxiv : the preprint server for biology·2026
Same author

Correction: Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.

Cancer research·2025
Same author

Moderate- to High-grade Blunt Liver and Spleen Injuries Warrant Repeat Imaging to Identify Treatable Complications: Results of the Radiographic Evaluation of Delayed Solid Organ Complications EAST Multicenter Trial.

Annals of surgery·2025
Same author

<i>CTHRC1</i> Expression Results in Secretion-Mediated, SOX9-Dependent Suppression of Adipogenesis: Implications for the Regulatory Role of Newly Identified CTHRC1<sup>+</sup>/PDGFR-Alpha<sup>+</sup> Stromal Cells of Adipose.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Sep 4, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K

Tranexamic acid: Beyond antifibrinolysis.

Igor Prudovsky1, Doreen Kacer1, Victoria Vieira Zucco1

  • 1Maine Medical Center Research Institute, Maine Medical Center, Scarborough, Maine, USA.

Transfusion
|July 14, 2022
PubMed
Summary

Tranexamic acid (TXA) is a vital antifibrinolytic medication. Beyond preventing blood loss, TXA demonstrates anti-inflammatory effects and cellular protection, suggesting broader therapeutic potential.

Keywords:
hemorrhageinflammationmitochondriaplasmintranexamic acid

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.8K

Related Experiment Videos

Last Updated: Sep 4, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.8K

Area of Science:

  • Pharmacology
  • Cell Biology
  • Trauma Medicine

Background:

  • Tranexamic acid (TXA) is a widely used antifibrinolytic drug for hemorrhagic trauma and surgical patients.
  • TXA functions by inhibiting plasminogen maturation, thereby preventing fibrinolysis and blood loss.
  • Emerging evidence suggests TXA possesses effects beyond antifibrinolysis, including anti-inflammatory and cytoprotective properties.

Purpose of the Study:

  • To review the current clinical applications of tranexamic acid.
  • To explore the mechanisms of action of TXA beyond its antifibrinolytic activity.
  • To elucidate the broader cellular, organ, and organism-level effects of TXA.

Main Methods:

  • Literature review of clinical studies on tranexamic acid.
  • Analysis of research investigating non-antifibrinolytic effects of TXA.
  • Synthesis of findings on TXA's impact on inflammation, cellular integrity, mitochondrial function, and melanogenesis.

Main Results:

  • TXA is effective in reducing blood loss in trauma and surgery.
  • TXA exhibits anti-inflammatory and edema-suppressing properties.
  • TXA demonstrates potential in protecting endothelial and epithelial cells, enhancing mitochondrial respiration, and inhibiting melanogenesis.

Conclusions:

  • Tranexamic acid offers significant benefits in managing hemorrhage.
  • TXA's therapeutic potential extends beyond antifibrinolysis, encompassing anti-inflammatory and protective cellular functions.
  • Further research into TXA's diverse mechanisms is warranted to optimize its clinical utility.